Unione Europea -
italiano -
EMA (European Medicines Agency)
zejula
glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - agenti antineoplastici - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.
Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
zejula 100 mg capsule
glaxosmithkline ag - niraparibum - capsule - kapsel: niraparibum 100 mg a niraparibi tosilas monohydricus, colore.: e 133, e 127, e 102, excipiens per la capsula. - onkologikum - synthetika
Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
zejula 100 mg compresse rivestite con film
glaxosmithkline ag - niraparibum - compresse rivestite con film - niraparibum 100 mg ut niraparibi tosilas monohydricus, cellulosum microcristallinum, lactosum monohydricum 34.66 mg, povidonum k 30, crospovidonum, silica colloidalis hydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (nigrum), pro compresso obducto. - onkologikum - synthetika